IMPEL PHARMACEUTICALS INC (IMPL) Stock Analyst Ratings
USA - NASDAQ:IMPL - US45258K1097 - Common Stock
0.2411 USD
-0.17 (-41.79%)
0.22 USD
-0.02 (-8.75%)
ChartMill assigns a Buy % Consensus number of 80% to IMPL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 40.8. This target is 16822.44% above the current price.
IMPL was analyzed by 8 analysts. The buy percentage consensus is at 80. So analysts seem to be have mildly positive about IMPL.
In the previous month the buy percentage consensus was at a similar level.
IMPL was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2022-11-15 | Wedbush | Downgrade | Outperform -> Neutral |
| 2022-08-25 | JonesTrading | Initiate | Buy |
| 2021-05-18 | Guggenheim | Initiate | Buy |
| 2021-05-18 | Wedbush | Initiate | Outperform |
IMPEL PHARMACEUTICALS INC / IMPL FAQ
Can you provide the average price target for IMPEL PHARMACEUTICALS INC stock?
8 analysts have analysed IMPL and the average price target is 40.8 USD. This implies a price increase of 16822.44% is expected in the next year compared to the current price of 0.2411.
How do analysts rate IMPEL PHARMACEUTICALS INC (IMPL)?
The consensus rating for IMPEL PHARMACEUTICALS INC (IMPL) is 80 / 100 . This indicates that analysts generally have a positive outlook on the stock.